X
skip to main content
Logo

The Terry Fox New Frontiers Program Project Grants (2017)


Description

A Terry Fox New Frontiers Program Project Grant provides support to a group of researchers conducting independent high-quality investigations in a complex area of cancer research. The purpose is to stimulate group interaction based on the premise that high impact work in complex areas of cancer research requires collaboration. The Terry Fox New Frontiers Program Project Grant is designed for researchers with complementary skills, who investigate different aspects of a given cancer relevant topic, the results of which will be realized more rapidly and efficiently than if the individual projects were to be funded as a series of independent operating grants. This long-standing funding opportunity has supported many of the best cancer research groups in Canada.

Purpose

To explore new frontiers in cure-oriented cancer research.


Scope

Support under this RFA is for multidisciplinary programs of excellence that contribute to well-defined research topics of relevance to cancer. The goal of each innovative and independently fundable research project and technology that comprise a Terry Fox New Frontiers Program Project Grant (PPG) is to provide new knowledge with the potential to transform cancer diagnosis, treatment and/or understanding of cancer biology. Proposals which address fundamental issues such as (i) hard-to-treat cancers, (ii) metastatic disease, (iii) mechanisms of disease progression and/or resistance, or (iv) cancer stem cells are welcomed in addition to other cancer-relevant topics.


Support offered

This RFA supports programs comprised of a minimum of three independent researchers and their research projects, and may also include one or more technology platforms that will be used by the projects. Support is offered, commencing on July 1, 2017, for:

  • New Applications of up to $750,000 per annum for a maximum of three years, and
  • Renewing Applications of up to $1,500,000 per annum for a maximum of five years.

Key Deadlines


Stage Dates Status
Submission of a Letter of Intent July 4, 2016 (5:00 pm PDT) Closed
Invitation to Submit a Full Application September 14, 2016 Closed
Submission of a Full Application November 14, 2016 (5:00 pm PST) Closed
Site Visits Held March/April 2017
Notice of Decision/Awards May 31, 2017  
Funding Starts July 1, 2017  




 Templates

Guidance provided








Summary of Letter of Intent stage

As described in the competition Request for Applications (RFA), The Terry Fox Research Institute (TFRI) has created a Program Project Grant Steering Committee on Research Excellence (PPG SCORE) which will oversee this year's competition. The committee reviewed 13 Letters of Intent (LOIs) on Tuesday August 30, 2016 in Toronto. All LOIs received were from established cancer researchers proposing to study important cancer questions in novel and innovative ways. The committee has recommended that six LOI teams be invited to prepare full applications.

Program Title

Project Leader

The Terry Fox New Frontiers Program Project Grant Exploring the Metabolic, Epigenetic and Microbiome Drivers of Inflammation-Driven Malignancy

Baksh, Shairaz

The Terry Fox New Frontiers Program Project Grant: Canadian Oncolytic Virus Consortium [COVCo]

Bell, John

Ultrasound and MRI for Cancer Therapy

Czarnota, Gregory

The Terry Fox New Frontiers Program Project in Directing GBM Differentiation

Dirks, Peter

Exploiting Pathogenic Mechanisms in Acute Leukemia for Clinical Translation

Karsan, Aly

The Terry Fox New Frontiers Program Project Grant in Porphysome Nanoparticle-Enabled Image-Guided Cancer Interventions

Zheng, Gang and Wilson, Brian





TFRI SCORE committee membership



 

 

David Rose, PhD  (chair)

Professor and Chair, Department of Biology, University of Waterloo

Ann Chambers, PhD

Director, Pamela Greenaway-Kohlmeier Translational Breast Cancer Unit, London Regional Cancer Program

Susan P.C. Cole, PhD, FRSC, FCAHS

Bracken Chair in Genetics & Molecular Medicine, Division of Cancer Biology & Genetics, Queens University

Nada Jabado, MD PhD

Professor, Department of Pediatrics, McGill University

Calum MacAulay, PhD

Head, and Distinguished Scientist, Imaging Unit, Integrative Oncology Department, British Columbia Cancer Agency

David Malkin, MD

POGO Chair in Childhood Cancer Control, Professor, Departments of Pediatrics and Medical Biophysics, University of Toronto

Medical Director, Pediatric Oncology Group of Ontario, Staff Oncologist, Division of Hematology/Oncology, Senior Scientist, Genetics and Genome Biology Program, The Hospital for Sick Children

David Wishart, PhD

Professor, Departments of Biological Sciences and Computer Science, University of Alberta

Jim Woodgett, PhD

Director of Research and Senior Investigator, Lunenfeld-Tanenbaum Research Institute, Sinai Health Systems











For inquiries, please contact:

Russell Watkins
Terry Fox Research Institute
675 West 10th Avenue
Vancouver, BC V5Z 1L3 Canada
Telephone: 1-604-675-8000 ext 7624
Email: rwatkins@tfri.ca

Back to Top